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ABSTRACT
Cofactor-independent phosphoglycerate mutase has been proposed as a therapeutic target for the treatment of 
trypanosomatid diseases. In this paper, we report the identification of compounds that could potentially be developed as 
selective inhibitors of cofactor-independent phosphoglycerate mutase from Leishmania mexicana (LmiPGAM). Virtual 
screening was used in this search, as well as compounds identified by high-throughput screening. A ligand-based virtual 
screen programme, ultra fast shape recognition with atom types (UFSRAT), was used to screen for compounds resembling 
the substrate/product, before a structure-based approach was applied using AutoDock 4 and AutoDock Vina in a consensus 
docking scheme. In this way eight selected compounds were identified. In addition, three compounds from the Library of 
Pharmacologically Active Compounds (LOPAC) were selected from the published results of high-throughput screening of 
this library. The inhibitory effects of these compounds were tested at a fixed concentration of 1 mM. The results showed 
that seven compounds inhibited LmiPGAM activity and of these, two compounds (one each from high-throughput and 
virtual screening) showed substantial inhibition (i.e. 14% and 49% remaining activity, respectively). Taken together, the 
findings from this study indicate that these compounds have potential as novel inhibitors that specifically target LmiPGAM.
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ABSTRAK
Fosfogliserat mutase bebas-kofaktor telah dicadangkan sebagai sasaran terapeutik bagi penyakit yang disebabkan 
oleh tripanosomatida. Di sini kami melaporkan pengenalpastian sebatian yang berpotensi untuk dibangunkan sebagai 
perencat kepada fosfogliserat mutase bebas-kofaktor daripada Leishmania mexicana (LmiPGAM). Saringan secara 
maya telah diaplikasikan dalam kajian ini, selain daripada beberapa jenis sebatian yang dikenalpasti melalui saringan 
berprosesan tinggi. Program saringan maya berasaskan ligan, Ultra Fast Shape Recognition with Atom Types (UFSRAT), 
telah digunakan untuk menyaring sebatian yang menyerupai substrat/produk, sebelum pendekatan berasaskan struktur 
digunakan menerusi program AutoDock 4 dan AutoDock Vina di dalam skim simulasi pengikatan ligan kepada reseptor 
(docking) yang konsensus. Melalui kaedah ini, lapan sebatian terpilih telah dikenal pasti. Selain daripada itu, tiga 
sebatian daripada Library of Pharmacologically Active Compounds (LOPAC) yang dikenal pasti melalui kaedah saringan 
berprosesan tinggi terhadap perpustakaan ini yang telah diterbitkan turut dipilih untuk analisis lanjutan. Kesan perencatan 
kesemua sebatian ini telah diuji pada kepekatan yang ditetapkan pada 1 mM. Hasil analisis ini telah menunjukkan bahawa 
tujuh sebatian merencat aktiviti LmiPGAM, dengan dua sebatian (masing-masing daripada saringan berprosesan tinggi 
dan maya) menunjukkan perencatan yang ketara (14% dan 49% baki aktiviti). Secara keseluruhannya, hasil daripada 
kajian ini menunjukkan bahawa sebatian ini berpotensi sebagai perencat novel yang spesifik kepada LmiPGAM.
Kata kunci: Analisis saringan maya; fosfogliserat mutase bebas-kofaktor; glikolisis; Leishmania mexicana 
INTRODUCTION
The family Trypanosomatidae includes various parasitic 
protists among which are species of the genus Leishmania. 
They are responsible for causing a range of cutaneous and 
visceral diseases such as ulcers, destructive lesions and kala 
azar, an infection of the liver and spleen that is usually fatal 
if untreated. Leishmania species are a continuous threat 
to the inhabitants of many parts of the world. According 
to the World Health Organisation (WHO-NTD 2015), 12 
million people from 98 countries worldwide are currently 
infected with these diseases. At present, anti-leishmanial 
treatment depends primarily on chemotherapy, with several 
drugs now available as treatment options. However, the 
limitations of these drugs (high cost, injections required, 
painful and long course of treatment and serious side effects 
and resistance) highlight the need for the discovery of 
more affordable, less toxic and orally-consumable drugs 
(Golgher et al. 2011).
 The essential role of carbohydrate metabolism in the 
survival of trypanosomatids has been well elucidated, 
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indicating that the glycolytic and/or gluconeogenic 
pathways play important roles (Verlinde et al. 2001). 
The cofactor-independent phosphoglycerate mutase 
(iPGAM), in particular, is an appealing drug target, as it 
exhibits no sequence or structural similarity with the 
corresponding enzyme in humans (Chevalier et al. 2000; 
Nowicki et al. 2009). Moreover, the enzyme is an essential 
component of both the glycolytic and gluconeogenic 
pathways and in this regard is of particular relevance in 
the pathogenic amastigote form of Leishmania species 
where gluconeogenesis (but not glycolysis) is an essential 
pathway (Naderer et al. 2006). By contrast, glycolysis is 
an essential pathway in the pathogenic bloodstream form 
of the related parasite Trypanosoma brucei. 
 Phosphoglycerate mutases (PGAMs, EC 5.4.2.1) 
(reviewed by Fothergill-Gilmore & Michels 1993) catalyse 
the interconversion of 3-phosphoglycerate (3PGA) and 
2-phosphoglycerate (2PGA) in both the glycolytic and 
gluconeogenic pathways. In humans and vertebrates, as 
well as yeasts and certain bacteria, the enzyme relies on 
2,3-bisphosphoglycerate as a cofactor for the catalytic 
function (cofactor-dependent dPGAMs). Cofactor-
independent iPGAMs, on the other hand, require divalent 
metal ions to support their activities and can be found in 
protists (including L. mexicana and T. brucei), plants, 
fungi, archaea, algae, some nematodes and bacteria. While 
the dPGAMs are usually dimers or tetramers, the iPGAMs 
(classified as members of the metal-dependent alkaline 
phosphatase superfamily) are predominantly monomeric 
enzymes. Since the two enzymes are evolutionarily 
unrelated, drug design against iPGAM from trypanosomatid 
parasites has been of particular interest. Amino acid 
sequence analysis of iPGAMs shows that they occur in 
two families, with the enzymes from trypanosomatids and 
plants in one family, and bacterial, algal and nematode 
enzymes in another family (Blackburn et al. 2014). The 
enzymes in the two families are very similar, but differ in 
the details of their dynamic properties and modes of action.
 Crystal structures of L. mexicana iPGAM (LmiPGAM) 
(PDB: 3IGY) (Nowicki et al. 2009), T. brucei iPGAM 
(PDB:3NVL) (TbiPGAM) (Mercaldi et al. 2012), various 
Bacillus species (Jedrzejas et al. 2000; Nukui et al. 2007) 
and Staphylococcus aureus (Roychowdhury et al. 2015) 
have been reported. All iPGAM structures show a two-
domain monomeric enzyme, which may be trapped in both 
open apoenzyme and closed ligand-bound conformations 
(Figure 1). In its closed conformation, the active site was 
inaccessible to the solvent, a situation which may correlate 
with disappointing results from high-throughput inhibitor 
screening (Crowther et al. 2014). 
 Since the main goal of our research was to identify new 
drugs for the treatment of leishmaniasis, a series of virtual 
screening strategies has been carried out with the aim of 
finding novel drug-like inhibitors. A ligand-based drug 
design experiment was employed by initialising similar 
compounds that resemble the natural ligands occupying the 
catalytic site. Subsequently, a series of docking and scoring 
experiments were conducted following a structure-based 
drug design approach, before compounds were selected for 
in vitro inhibition analysis. In parallel, a preliminary high-
throughput screen was conducted at the National Institutes 
of Health (NIH), Bethesda, MD, USA (http://pubchem.ncbi.
nlm.nih.gov/assay/assay.cgi?aid=504639), the goal of 
which was to assess the ability of specific compounds to 
inhibit enzyme activity in vitro. Both the virtual and high-
throughput screening approaches offer new hope for the 
discovery of novel drug-like inhibitors that specifically 
target LmiPGAM. 
MATERIALS AND METHODS
PROTEIN EXPRESSION AND PURIFICATION
The bacterial expression of C-terminally His6 tagged 
LmiPGAM and subsequent cell lysis were performed as 
described previously. The protein was purified by metal-
affinity chromatography via the His tag LEHHHHHH (Fuad 
et al. 2011), followed by ion-exchange chromatography 
(Blackburn et al. 2014). Briefly, the LmiPGAM was 
initially passed through a 5 mL IMAC Hitrap HP column 
(GE Healthcare), pre-charged nickel, and after washing 
was eluted by 500 mM imidazole. The pooled LmiPGAM 
fractions were applied to a 1 mL MonoQ 5/50 GL anion-
exchange column (GE Healthcare) after a washing step with 
buffer A (20 mM HEPES (Sigma Life Sciences) pH7.6). 
The protein was eluted with buffer B (20 mM HEPES, 1 M 
NaCl (Fisher Scientific) pH7.6) in a linear gradient, for 80 
column volumes and yielded three main peaks as described 
by Blackburn et al. (2014). These were pooled separately 
and buffer-exchanged into 20 mM TEA-HCl (Sigma Life 
Sciences) pH7.6 and 50 mM NaCl (Fisher Scientific) using 
a 53 mL HiPrep 26/10 desalting column (GE Healthcare). 
The major peak was used for activity measurements 
and corresponded to LmiPGAM in its open conformation 
(Blackburn et al. 2014). The protein concentration was 
measured as described previously (Fuad et al. 2011). The 
enzyme was stored in the cold room (4˚C) before being 
used for the subsequent inhibition assays. 
DOCKING PARAMETERS AND CONTROL EXPERIMENTS 
FOR VIRTUAL SCREENING
Water molecules and other hetero atoms were removed 
from the structures and the program PDB2PQR 1.8 (Dolinsky 
et al. 2007) was used to assign position-optimised hydrogen 
atoms, utilising the additional PropKa (Li et al. 2005) 
algorithm with a pH of 7.4 to predict protonation states. 
The MGLTools 1.5.4 utility prepare_receptor4.py was used 
to assign Gasteiger charges to atoms. Hydrogen atoms 
were assigned to ligand structures using OpenBabel 2.3.1 
(O’Boyle et al. 2011), utilising the -p option to predict 
the protonation states of functional groups at pH7.4. The 
MGLTools utility prepare_ligand4.py was used to assign 
Gasteiger charges and rotatable bonds and MOPAC 2012 
was used to calculate the charge of the zinc ion. As Vina 
1.1.2 (Trott & Olson 2010) and Autodock 4.2.3 (Cosconati 
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et al. 2010; Huey et al. 2007) both use the same .pdbqt 
format for their input, the same prepared files could be 
used for each. A grid box that encompassed the maximum 
dimensions of the ligand plus 12 Å in each direction was 
used. The starting translation and orientation of the ligand 
and the torsion angles of all rotatable bonds were set to 
random. The Autogrid grid point spacing was set at 0.2 
Å. The Autodock parameter file specified 10 Lamarckian 
genetic algorithm runs, 2,000,000 energy evaluations and 
a population size of 300. Each docking program was used 
to automatically dock the cognate ligand into the 2PGA 
binding pocket of the crystal structure of the closed-form 
of LmiPGAM (PDB: 3IGY). 
CURATION OF THE VIRTUAL CHEMICAL LIBRARY
The screening compound stock lists in SDF format of 
ChemBridge, Asinex, Maybridge, Enamine, LifeChemicals, 
Specs, InterBioScreen, ChemDiv and KeyOrganics were 
merged. Salts were stripped out using Sieve 3.1.0 (de 
Winter 2014) and duplicates removed using canonical 
SMILES string comparison via Open Babel 2.3.1. The 
supplied 2D coordinates were converted into 3D using 
Concord 4.08. Because the aim was to identify initial 
lead-like hits suitable for optimisation into more drug-
like molecules, the virtual library was filtered according 
to Oprea ‘lead-like’ rules (H-bond acceptors ≤ 9; H-bond 
donors ≤ 5; MW ≤460; cLogP between -4.6 and 4.2; cLogS 
≥ -5; Number of rings ≤ 4; Number of rotatable bonds ≤ 
9) (Hann & Oprea 2004). This left 1,137,587 molecules. 
A multi-conformer version of this virtual library was 
produced using Multiconf-DOCK (Sauton et al. 2008); an 
average of 4.25 conformers per compound were generated 
depending on flexibility; this resulted in a virtual library 
containing a total of 4,840,093 conformers.
VIRTUAL SCREENING
An initial ligand-based pharmacophore screen was carried 
out. 2PGA from the crystal structure was used as a search 
term. The programs UFSRAT (Shave et al. 2015), ROCS 
3.0.0 (Hawkins et al. 2007) and a Wiener index similarity 
comparison algorithm available as part of EDULISS 2.0 
(Hsin et al. 2011) were used to search the virtual library 
for molecules with different types of similarity to the 
known ligands. The UFSRAT search of the multi-conformer 
library returned 7,268 molecules, ROCS returned 10,002 and 
EDULISS 10,000. UFSRAT was accessed through the Centre 
for Translational and Chemical Biology, The University 
of Edinburgh website (http://opus.bch.ed.ac.uk/ufsrat/).
 In addition, the rigid-body docking program LIDAEUS 
(Taylor et al. 2008) (http://opus.bch.ed.ac.uk/lidaeus/) was 
used to dock the conformer virtual library into the 2PGA 
binding site of the LmiPGAM crystal structure. The results 
were ranked according to LIDAEUS score, the top 28,757 
compounds from this list merged with the results from the 
ligand-based methods described above and the duplicates 
removed. This resulted in 21,603 unique molecules which 
were docked into LmiPGAM using Vina. Docked poses were 
scored using both Vina’s internal scoring algorithm and 
X-Score 1.2 (Wang et al. 2002); these scores were used 
via a ‘rank-by-rank’ consensus scheme (Wang & Wang 
(a)
(b)
FIGURE 1. (a) The closed-form crystal structure of LmiPGAM (Nowicki et al. 2009; PDB ID: 3IGY) showing the phosphatase and 
transferase domains, and with 2PGA in the active site. (b) The 16 residues which are conserved in the active site. The green text 
indicates residues in the phosphatase domain, whereas the red text indicates residues in the transferase domain. The spheres labelled 
M1 and M2 correspond to the divalent metal-binding sites which are occupied by Co2+ in the crystal structure
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2001) to create a ranked list. The top 200 compounds 
were then used as search terms for another iteration of the 
ligand-based virtual screening methods as described above. 
This resulted in 7,386 unique molecules, which were also 
docked using Vina. The top 1,920 of these were docked 
using Autodock, of which 1,196 predicted binding modes 
matched those of Vina (coordinate root-mean-square 
deviation < 2.0 Å). These ‘consensus docked’ (Houston 
& Walkinshaw 2013) molecules were also scored using 
DrugScore 1.2 (Gohlke et al. 2000). A final ranked list 
was prepared via rank-by-rank scheme, taking the Vina, 
Autodock, X-Score and DrugScore scores into account.
QUANTITATIVE HIGH-THROUGHPUT SCREENING
Quantitative high-throughput screening (qHTS) was 
performed by using the Kinase-Glo Plus® reagent 
(Promega), which quantifies the amount of ATP in a sample 
following a kinase reaction. A 1536-well plate-based 
assay was used in the glycolytic direction with purified 
LmiPGAM, with the addition of enolase (ENO) and pyruvate 
kinase (PYK) as coupling enzymes and was done in the 
presence of 0.13 mM CoCl2. The 1280 compound Library 
of Pharmacologically Active Compounds (LOPAC®) 
(Sigma-Aldrich) was used for a preliminary screen. A 
7-point dilution series for each compound was used and 
the enzymes and compounds were incubated for 60 min 
prior to the addition of the Kinase-Glo reagent (http://
pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=504639). 
IN VITRO INHIBITION ANALYSIS WITH SELECTED 
COMPOUNDS
A preliminary screen was performed according to the 
plate-based assay for the activity of iPGAM coupled with the 
oxidation of NADH to NAD+ by lactate dehydrogenase (LDH) 
in the presence of ENO and PYK as reported previously 
(Fuad et al. 2011). A final concentration of 0.01 mg/mL 
LmiPGAM was incubated with a final concentration of 1 
mM CoCl2 at 25˚C for 1 h, before 1 mM of compounds was 
added, followed by a further 1 h incubation. The reaction 
was started by the addition of 0.01 mg/mL iPGAM that has 
been incubated with 1 mM CoCl2 and selected compounds 
into the reaction mixture containing 100 mM TEA-HCl 
buffer pH7.6, 5 mM MgCl2, 50 mM KCl, 1 mM NADH, 1 
mM ADP, 1 unit of ENO, 2 units of PYK and 3 units of LDH 
(1 unit of enzyme converts 1.0 mmole of substrate per 
min at pH7.4 at 25oC). The assays were done in triplicate. 
All stock solutions of the compounds were prepared by 
dissolving them with 100% DMSO, except for compounds 5 
and 10, which were dissolved with 50% DMSO, before being 
further diluted with 200 mM TEA-HCl pH7.6 to prepare a 
10 mM stock solution (Fuad 2012). Compound 1 was from 
Enamine (Kiev, Ukraine) and compounds 2 and 3 from 
Sigma-Aldrich. Compounds 4-7 were from Enamine and 
compounds 8-11 from InterBioScreen (Moscow, Russia). 
Cobalt was the divalent metal used in the assay because it 
hyperactivates LmiPGAM in vitro (Fuad et al. 2011). The 
presence of residual Ni2+ in purified LmPGAM from the 
metal-affinity column was regarded as unlikely because the 
enzyme had experienced ion-exchange and gel filtration 
column purification steps (in the absence of added divalent 
metals) after the metal-affinity column step.
RESULTS AND DISCUSSION
UFSRAT IDENTIFIES SMALL MOLECULE 
ANALOGUES OF 2PGA/3PGA
The closed-form crystal structure of LmiPGAM comprises 
two distinct domains that play individual roles in the 
catalytic function of the enzyme. Two Co2+ ions were 
coordinated within the active site, together with both 
substrate and product, which were present at equal 
occupancies (Figure 1(a)) (Nowicki et al. 2009). It can 
be seen that residues from both the phosphatase and 
transferase domains contribute to ligand binding (Figure 
1(b)). The small and poorly accessible active site makes 
the prediction of interactions with drug-like compounds 
difficult. UFSRAT has the ability to identify molecules that 
are similar to the substrate 3PGA or product 2PGA (Figure 
2), thus increasing the likelihood of discovering small 
molecule inhibitors that may be inserted into the active 
site of LmiPGAM.
 The overall shape similarities were not the only 
consideration in the UFSRAT algorithm, as it also examines 
the types and molecular topology of the existing atoms. 
The geometrical distribution of atoms was divided into 
four categories based on all atom types, hydrophobicity, 
hydrogen acceptor, or hydrogen donor atoms (Fuad 
2012; Shave et al. 2015). Taking these descriptors into 
consideration and using 3PGA/2PGA as the query molecules, 
a search was carried out, examining the contents of a large 
multi-conformer library comprising 4,853,000 molecules 
from various suppliers (Chembridge, Asinex, Maybridge, 
Enamine, LifeChemicals (InfLab) Specs, InterBioScreen 
and ChemDiv) to identify candidates similar to the query 
molecules. In this process, similarity was evaluated 
through the scoring function, where 0 indicates the least 
similar compounds, whereas a score near to 1 suggests 
a close resemblance. The scores associated with the five 
compounds most closely resembling 3PGA ranged from 
0.739 to 0.770, while the scores of compounds similar to 
2PGA ranged from 0.708 to 0.728 (data not shown).
MOLECULAR DOCKING FOR STRUCTURE-BASED 
VIRTUAL SCREENING
Molecular docking was employed using both AutoDock 
4 and AutoDock Vina to generate a grid map based on 
the active site region. The map was subsequently used 
to screen approximately 200 compounds obtained from 
UFSRAT. The predicted binding affinity was calculated for 
all 200 compounds using an algorithm that was applied in 
both programmes. The results, in general, met the criteria 
that are commonly accepted by Lipinski’s rule of 5 for 
molecule drug-likeliness (Lipinski et al. 1997; Taylor et al. 
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2008). Both the AutoDock4 and AutoDock Vina results 
were individually assessed in terms of the scores, which 
were based on the binding affinities. Strong interactions 
were indicated by negative and low free energy of 
binding (ΔGbind, kcal/mol) values, which also signified 
that the potential inhibitor was in its most favourable 
conformation (Messaoudi et al. 2013). 
 A proprietary combinatorial virtual screening 
scheme, which is still under development at Edinburgh 
University, was also used to obtain comparable and 
accurate results. This workflow combines both similarity 
searches and docking algorithms to provide a consensus 
prediction of possible molecular interactions. This 
process involved a cycle of parallel fast flexible docking 
and similarity search algorithms comprising AutoDock, 
AutoDock Vina and LIgand Discovery At Edinburgh 
(LIDAEUS), which were employed against the Edinburgh 
University LIgand Selection System (EDULISS) database. 
It is relevant to mention that Zn2+ atoms were included 
in this analysis, as it was reported that Zn2+ might be the 
biologically relevant metal for trypanosomatid iPGAM 
(Fuad et al. 2011). Compounds from the three programs 
were evaluated based on the binding affinity, solubility, 
range of chemical classes covered and specific chemical 
groups contained, which may resemble the properties 
of the substrate and product. Eight of these compounds 
(Figure 3) were subsequently selected for the inhibitory 
analysis. 
ANALYSIS OF POTENTIAL INHIBITORS
In parallel with the virtual screening work (which yielded 
the eight compounds in Figure 3), three additional 
compounds were selected from preliminary qHTS of 
LmiPGAM using the LOPAC® library (http://pubchem.ncbi.
nlm.nih.gov/assay/assay.cgi?aid=504639) and are shown 
in Figure 4. The eleven compounds thus identified by both 
screening methods were tested for inhibitory activity. 
Their structures are shown in Figures 3 and 4. 
 The enzyme assay described in materials and 
methods was used and the potential inhibitory effects on 
the coupling enzymes (ENO, PYK and LDH) were assessed 
in the absence of LmiPGAM when the assay reaction 
included 2PGA instead of 3PGA. The concentration of each 
compound was fixed at 1 mM and the inhibitory effect 
was expressed as the percentage of remaining activity of 
LmiPGAM after the addition of the compounds (Figure 5). 
Of the 11 compounds, two showed substantial specific 
inhibition of LmiPGAM (compound 2 from the LOPAC® 
screen, 86% inhibition; compound 7 from the virtual 
screen, 51% inhibition). It can be noted that the inhibitory 
effect of compound 3 seemed to act at the level of one 
or more of the coupling enzymes and not specifically 
on LmiPGAM. The assay with compound 9 showed no 
absorbance at 340 nm, indicating that the NADH in the 
assay had been completely converted to NAD+. This effect 
was observed in both enzyme samples and was therefore 
not specific for LmiPGAM. Compounds 4 and 5 from 
(a) (b)
FIGURE 2. The query molecules which were used for UFSRAT: (a) 3PGA and (b) 2PGA
FIGURE 3. A compilation of compounds identified from the structure-based virtual screens
 Compound 4  Compound 5  Compound 6  Compound 7
 Compound 8  Compound 9  Compound 10  Compound 11
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the virtual screen showed modest specific inhibition of 
LmiPGAM.
 No potent inhibitors of trypanosomatid iPGAMs have 
previously been reported other than non-specific metal 
chelators. Thus, an important implication of our findings 
was the potential for some of the compounds we identified 
to be developed as specific inhibitors for LmiPGAM. 
Moreover, the structural and mechanistic similarities 
between LmiPGAM and TbiPGAM mean that inhibitors of 
the former enzyme may well be relevant to inhibition of 
the latter. This is of special significance in the context of 
the recent publication of the results of two high-throughput 
screens of iPGAM from the nematodes Brugia malayi and 
Caenorhabditis elegans (Crowther et al. 2014). They 
concluded that iPGAM has limited druggability. However, 
it is relevant to note that nematode and trypanosomatid 
iPGAMs belong to different families, with different 
mechanisms of opening and closing their two-domain 
structures, as well as different closed structures (Blackburn 
et al. 2014). Furthermore, the recent description of a spring-
loaded mechanism inherent to the iPGAM structure which 
favours the open conformation in the absence of ligands is 
also of crucial importance (Roychowdhury et al. 2015). In 
the context of drug discovery, all these observations add up 
to encourage the use of virtual screening on the one hand 
and on the other of using enzyme assay conditions that may 
facilitate ligand binding, such as extended pre-incubation 
periods. 
CONCLUSION
Making use of both virtual and high-throughput screens, 
we have identified several inhibitors for LmiPGAM, 
which could serve as starting points for drug discovery 
 Compound 1  Compound 2             Compound 3
FIGURE 4. Compounds identified by high-throughput screening
FIGURE 5. Inhibition analysis for LmiPGAM plus coupling enzymes (red bars) and for the coupling enzymes alone (blue bars). 
3PGA or 2PGA were used as the starting reagents for the two assays, respectively. The assays were carried out with 1 mM of each 
compound as described in materials and methods. The assay with compound 9 showed no absorbance at 340 nm 
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for trypanosomatid iPGAMs. The results showed that two 
compounds gave substantial inhibition of 86% (compound 
2) and 51% (compound 7) at 1 mM. Interestingly, 
compound 7 was discovered from the virtual screen, 
whereas compound 2 was one of the compounds obtained 
from HT screening. 
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